XOMA Awarded $65 Million Biodefense Contract by NIAID to Advance Drug Candidates Against Botulism Toxins Into Clinical Trials Sep 09, 2008 1:57pm EDT
XOMA 052 Clinical Results Support New Type 2 Diabetes Therapeutic Approach of Targeting Inflammatory Damage to Insulin-Producing Cells Sep 08, 2008 5:00am EDT
XOMA Begins Phase 2a Clinical Trial to Evaluate XOMA 629 Topical Gel as a Treatment for the Common Skin Disease, Impetigo Jul 24, 2008 4:41pm EDT
XOMA 052 Phase 1 Data to be Presented At European Association for the Study of Diabetes Annual Meeting Jul 15, 2008 7:30am EDT
XOMA 052 Demonstrates Anti-Inflammatory Effect in Arthritis Animal Studies; Data Presented At FOCIS Jun 07, 2008 2:00pm EDT
XOMA 052 Demonstrates Anti-Inflammatory Effects in Diabetes Animal Studies; Data Presented At ADA Jun 07, 2008 1:00pm EDT
XOMA to Present At the Needham Biotechnology and Medical Technology Conference On June 11 Jun 05, 2008 4:35pm EDT
XOMA to Present At the Rodman and Renshaw Global Healthcare Conference On May 20 May 14, 2008 4:35pm EDT
